HDL biology
Statin-driven normalisation of HDL lipid composition lags behind LDL and apoB reduction, revealing role of CETP (J Clin Lipidol 2018)
Original title: Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP
Twelve insulin-resistant, obese men with mixed dyslipidemia of metabolic syndrome were treated with pitavastatin and followed at 6, 42, and 180 days. LDL cholesterol, apoB, and triglycerides fell rapidly and were essentially normalised by day 42, but cholesteryl ester transfer protein (CETP) activity and mass declined only progressively, by 18 and 16 percent respectively, with triglyceride depletion and cholesteryl ester enrichment of HDL particles, and normalisation of the HDL cholesteryl ester to triglyceride ratio not complete until day 180. The results reveal a duality in statin action: rapid clearance of atherogenic apoB-containing lipoproteins is followed much later by CETP-mediated normalisation of the HDL lipid core, which the authors propose as a metabolomic marker of statin impact on HDL structure and function.
Original abstract
Background: Statins impact the metabolism, concentrations, composition, and function of circulating lipoproteins.
Objective: We evaluated time course relationships between statin-mediated reduction in atherogenic apolipoprotein B (ApoB)-containing particles and dynamic intravascular remodeling of ApoAI-containing lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome.
Methods: Insulin-resistant, hypertriglyceridemic, hypercholesterolemic, obese males (n = 12) were treated with pitavastatin (4 mg/d) and response evaluated at 6, 42, and 180 days.
Results: Reduction in low-density lipoprotein (LDL) cholesterol, ApoB, and triglycerides (TGs) was essentially complete at 42 days (-38%, -32%, and -35%, respectively); rapid reduction equally occurred in remnant cholesterol, ApoCII, CIII, and E levels (day 6; -35%, -50%, -23%, and -26%, respectively). Small dense LDLs (LDL4 and LDL5 subpopulations) predominated at baseline and were markedly reduced on treatment (-29% vs total LDL mass). Cholesteryl ester (CE) transfer protein activity and mass decreased progressively (-18% and -16%, respectively); concomitantly, TG depletion (up to -49%) and CE enrichment occurred in all high-density lipoprotein (HDL) particle subpopulations with normalization of CE/TG mass ratio at 180 days. ApoAI was redistributed from LpAI to LpAI:AII particles in HDL2a and HDL3a subpopulations; ApoCIII was preferentially depleted from LpAI:AII-rich particles on treatment.
Conclusion: Overall, statin action exhibits duality in mixed dyslipidemia, as CE transfer protein-mediated normalization of the HDL CE/TG core lags markedly behind subacute reduction in elevated levels of atherogenic ApoB-containing lipoproteins. Normalization of the HDL neutral lipid core is consistent with enhanced atheroprotective function. The HDL CE/TG ratio constitutes a metabolomic marker of perturbed HDL metabolism in insulin-resistant states, equally allowing monitoring of statin impact on HDL metabolism, structure, and function.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.